Clinical Trial Update: A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) [Phase 3]

View source ↗

Summary

This clinical trial update reports results from a Phase 3 study of letermovir (MK-8228) for preventing cytomegalovirus infection in Chinese hematopoietic stem c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus Infection | Phase 3 | Status: COMPLETED | Results posted: 2025-03-25